Novel compound heterozygous mutations of DOCK2 associated with early-onset recurrent infections
- 1Department of Rheumatology and Immunology, Shenzhen Children’s Hospital
- 2Department of Pediatrics, Baiyun Hospital Affiliated to Guizhou Medical University
Abstract
Introduction: Dedicator of cytokinesis 2 (DOCK2) deficiency is a rare combined immunodeficiency characterized by defects in both cellular and humoral immunity and caused by pathogenic mutations in the DOCK2 gene. Herein, we report a 3-year-8-month-old Chinese girl presenting with recurrent infections, immune thrombocytopenia (ITP), elevated IgE levels, and a hemophagocytic lymphohistiocytosis (HLH)-like episode to broaden the clinical phenotype spectrum of the DOCK2 defect.
Methods: All tests and molecular genetic analyses were performed after obtaining informed consent from the parents. Demographic, clinical, and laboratory findings were abstracted from outpatient and inpatient encounters. Whole-exome sequencing (WES) was performed on peripheral blood cells to identify the genetic etiology, followed by immunological evaluation (including lymphocyte subset analysis, T-cell receptor Vβ repertoire analysis, and neutrophil oxidative function assays) and in silico prediction. Sanger sequencing was used to confirm the identified variants.
Results: WES identified two novel compound heterozygous variants in DOCK2 (c. 106 C>T, p.R36X and c. 2150T>C, p.L717P), each inherited from one parent. Immunological evaluation revealed combined immune defects involving T cells and B cells, including reduced T/B cell subsets, skewed TCR repertoire, and impaired T cell proliferation. In silico analyses indicated that the variants affect highly conserved residues and are predicted to disrupt protein structure. The patient received supportive treatment, regular intravenous immunoglobulin replacement therapy, and sulfonamide prophylaxis, resulting in effective disease control.
Discussion: This case expands the genotypic and phenotypic spectrum of DOCK2 deficiency and highlights its critical role in human immune regulation. It also underscores the importance of early genetic diagnosis to guide timely clinical management. However, functional validation experiments were not performed to further confirm the pathogenicity of the identified variants, and additional protein expression studies are warranted.
Related
- Compound‐Heterozygous PLVAP Missense Variants Associated With Attenuated Protein‐Losing Enteropathy (DIAR10)
- Novel Compound Heterozygous RECQL4 Pathogenic Variants and Associated Phenotypes in a Chinese Patient With Rothmund-Thomson Syndrome: Case Report and Literature Review.
- Novel Compound Heterozygous CEP152 Variants Associated with Atypical Seckel Syndrome 5 in a Chinese Child: Functional Characterization of a Novel Splice-Site Variant and Expansion of the Genotype-Phenotype Spectrum.
- Heterozygous Mutations in MAP3K7 , Encoding TGF-β-Activated Kinase 1, Cause Cardiospondylocarpofacial Syndrome
- Hyperphosphatasia With Intellectual Disability (Mabry Syndrome) due to Compound Heterozygous PIGO Variants: First Molecularly Characterized Case in French Guiana: A Case Report and Review of the Literature.
BibTeX
@article{yang2026novel,
title = {{Novel compound heterozygous mutations of DOCK2 associated with early-onset recurrent infections}},
author = {Zhi Yang and Linlin Wang and Yang Wang and Xiaona Zhu and Yanyan Huang and Ying Luo and Jun Yang and Tingyan He},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1830547},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1830547/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Novel compound heterozygous mutations of DOCK2 associated with early-onset recurrent infections
AU - Zhi Yang
AU - Linlin Wang
AU - Yang Wang
AU - Xiaona Zhu
AU - Yanyan Huang
AU - Ying Luo
AU - Jun Yang
AU - Tingyan He
PY - 2026
DA - 2026/10/26
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1830547
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1830547/full
AB - Introduction: Dedicator of cytokinesis 2 (DOCK2) deficiency is a rare combined immunodeficiency characterized by defects in both cellular and humoral immunity and caused by pathogenic mutations in the DOCK2 gene. Herein, we report a 3-year-8-month-old Chinese girl presenting with recurrent infections, immune thrombocytopenia (ITP), elevated IgE levels, and a hemophagocytic lymphohistiocytosis (HLH)-like episode to broaden the clinical phenotype spectrum of the DOCK2 defect. Methods: All tests and molecular genetic analyses were performed after obtaining informed consent from the parents. Demographic, clinical, and laboratory findings were abstracted from outpatient and inpatient encounters. Whole-exome sequencing (WES) was performed on peripheral blood cells to identify the genetic etiology, followed by immunological evaluation (including lymphocyte subset analysis, T-cell receptor Vβ repertoire analysis, and neutrophil oxidative function assays) and in silico prediction. Sanger sequencing was used to confirm the identified variants. Results: WES identified two novel compound heterozygous variants in DOCK2 (c. 106 C>T, p.R36X and c. 2150T>C, p.L717P), each inherited from one parent. Immunological evaluation revealed combined immune defects involving T cells and B cells, including reduced T/B cell subsets, skewed TCR repertoire, and impaired T cell proliferation. In silico analyses indicated that the variants affect highly conserved residues and are predicted to disrupt protein structure. The patient received supportive treatment, regular intravenous immunoglobulin replacement therapy, and sulfonamide prophylaxis, resulting in effective disease control. Discussion: This case expands the genotypic and phenotypic spectrum of DOCK2 deficiency and highlights its critical role in human immune regulation. It also underscores the importance of early genetic diagnosis to guide timely clinical management. However, functional validation experiments were not performed to further confirm the pathogenicity of the identified variants, and additional protein expression studies are warranted.
SN - 1664-3224
ER -